EUVIMEDEUVIMED entdecken
Open Access

Psychedelic Drug Legislative Reform and Legalization in the US

Joshua S Siegel, James E Daily, Demetrius A Perry, Ginger E Nicol

JAMA Psychiatry · 2023

DOI: 10.1001/jamapsychiatry.2022.4101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Psychiatry, 2023. Verfasst von Joshua S Siegel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Washington University in St Louis, St Louis, Missouri. Hauptthemen laut MEDLINE: Hallucinogens, N-Methyl-3,4-methylenedioxyamphetamine. Die Arbeit wurde bisher 181-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NIDA NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Psychedelic drugs are becoming accessible in the US through a patchwork of state legislative reforms. This shift necessitates consensus on treatment models, education and guidance for health care professionals, and planning for implementation and regulation.

Objective

To assess trends in psychedelics legislative reform and legalization in the US to provide guidance to health care professionals, policy makers, and the public. Evidence Review Data were compiled from legislative databases (BillTrack50, LexisNexis, and Ballotpedia) from January 1, 2019, to September 28, 2022. Legislation was identified by searching for terms related to psychedelics (eg, psilocybin , MDMA , peyote , mescaline , ibogaine , LSD , ayahuasca , and DMT ). Bills were coded by an attorney along 2 axes: which psychedelic drugs would be affected and in what ways (eg, decriminalization, funding for medical research, and right to try). To explore drivers and rates of legislative reform, data were compared with other state indices including 2020 presidential voting margins and marijuana legislative reform.

Findings

Twenty-five states have considered 74 bills (69 legislative initiatives, 5 ballot measures); 10 bills were enacted, and 32 were still active. The number of psychedelic reform bills introduced during each calendar year increased steadily from 5 in 2019 to 6 in 2020, 27 in 2021, and 36 in 2022. Nearly all bills specified psilocybin (67 [90%]), and many also included MDMA (3,4-methylenedioxy-methamphetamine; 27 [36%]). While bills varied in their framework, most (43 [58%]) proposed decriminalization, of which few delineated medical oversight (10 of 43 [23%]) or training and/or licensure requirements (15 of 43 [35%]). In general, bills contained less regulatory guidance than the enacted Oregon Measure 109. While early legislative efforts occurred in liberal states, the margin between liberal and conservative states has decreased over time (although the difference was not significant), suggesting that psychedelic drug reform is becoming a bipartisan issue. In addition, an analytic model based on marijuana legalization projected that a majority of states will legalize psychedelics by 2034 to 2037. Conclusions and Relevance Legislative reform for psychedelic drugs has been proceeding in a rapid, patchwork fashion in the US. Further consideration should be given to key health care issues such as establishing (1) standards for drugs procured outside the medical establishment, (2) licensure criteria for prescribers and therapists, (3) clinical and billing infrastructure, (4) potential contraindications, and (5) use in special populations like youths, older adults, and pregnant individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensN-Methyl-3,4-methylenedioxyamphetaminePregnancyFemaleAdolescentHumansAgedPsilocybinMescalineEducational Status

Substanzen

HallucinogensPsilocybinN-Methyl-3,4-methylenedioxyamphetamineMescaline

Autor:innen und Institutionen

  • Department of Psychiatry, Washington University in St Louis, St Louis, Missouri.
  • Center for Empirical Research in the Law, Washington University in St Louis, St Louis, Missouri.

Förderung

  • NIMH NIH HHS
  • NIDA NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Siegel, J. S., Daily, J. E., Perry, D. A., & Nicol, G. E. (2023). Psychedelic Drug Legislative Reform and Legalization in the US. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2022.4101

Vancouver

Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic Drug Legislative Reform and Legalization in the US. JAMA Psychiatry. 2023. doi:10.1001/jamapsychiatry.2022.4101

BibTeX
@article{Siegel2023,
  author = {Siegel, Joshua S and Daily, James E and Perry, Demetrius A and Nicol, Ginger E},
  title = {Psychedelic Drug Legislative Reform and Legalization in the US},
  journal = {JAMA Psychiatry},
  year = {2023},
  doi = {10.1001/jamapsychiatry.2022.4101}
}
Kostenlos starten →